Retrospective Analysis Of Tyrosine Kinase Inhibitors In The Treatment Of Chronic Myeloid Leukemia

OBJECTIVE To evaluate therapeutic efficacy of tyrosine kinase inhibitors(TKI)in the treatment of early diagnosis Chronic Myeloid Leukemia(CML),and discuss the effect factors of TKI.METHODS In retrospective study,55 CML patients were collected from the First Affiliated Hospital of Chongqing University School of Medicine during 2013.1.1-2017.12.31.Among them,31 cases were given imatinib 400mg qd,4 cases were given nilotinib 400mg bid and 20 cases were given dasatinib 100mg qd.Therapeutic efficacy was evaluated by using Guidelines for diagnosis and treatment of chronic myeloid leukemia in China in 2016,hematology and molecular remission in 12 months after use TKI was observed and single factor analysis was conducted for different factor types.RESULTS The first generation of TKI and the second generation TKI major molecular remission rate(MMR)were 38.5%and 79.2%respectively on 12th,and undetectable minimal residual disease(UMRD)were 23.1%and 62.5%respectively,and the differences are statistically significant(P<0.05).The overall survival rate(OS)and event free survival(EFS)of the two generation TKI group were higher than that of the first generation TKI,but the difference is not statistically significant(P>0.05).But Single factor analysis showed that the various items that may affect TKI’s efficacy were not statistically significant(P>0.05).CONCLUSIONS Among TKI types,the long-term survival of TKI is similar,but molecular remission rate of the second generation TKI much better than the first generation of TKI,and general situation of patients had no effect on therapeutic efficacy of TKI,so,CML patients who chose to treat the second generation TKI were more likely to get a better molecular remission,and get more chance to discontinuation of TKI.